title: Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics.
abstract: We conducted a randomized, double-blind, placebo-controlled trial to compare a 3-day quinine-clindamycin regimen (group QC) with a 7-day quinine regimen (group Q) for the treatment of uncomplicated Plasmodium falciparum malaria in travelers returning from the tropics. A total of 55 and 53 patients in groups Q and QC were analyzed, respectively. Adverse effects were similar in both groups, although two patients in group Q had severe adverse reactions, leading to the cessation of treatment. The 28-day cure rate for the evaluated patients (per-protocol analysis) was 100% for group QC, whereas it was 96.3% for group Q (P = 0.5). The 28-day cure rate in the intention-to-treat analysis was 96.2% for group QC, whereas it was 94.6% for group Q (P = 1). There were no significant differences between the two regimens with regard to parasite and fever clearance times. Our study shows that the 3-day quinine-clindamycin regimen is well tolerated and compares favorably with a 7-day quinine treatment. This short-term regimen had previously been evaluated only in areas of endemicity. According to our results, the 3-day quinine-clindamycin regimen may be an alternative for the treatment of imported uncomplicated P. falciparum malaria in travelers returning from the tropics.
authors.affiliation: Service des Maladies Tropicales et Infectieuses, CHU Nord, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Parola
authors.forename: S
authors.initials: S
authors.lastname: Ranque
authors.forename: S
authors.initials: S
authors.lastname: Badiaga
authors.forename: M
authors.initials: M
authors.lastname: Niang
authors.forename: O
authors.initials: O
authors.lastname: Blin
authors.forename: J J
authors.initials: JJ
authors.lastname: Charbit
authors.forename: J
authors.initials: J
authors.lastname: Delmont
authors.forename: P
authors.initials: P
authors.lastname: Brouqui
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000962:Antimalarials / Q000009:adverse effects / Q000627:therapeutic use*; D002981:Clindamycin / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D011803:Quinine / Q000009:adverse effects / Q000627:therapeutic use*; D014195:Travel; D016896:Treatment Outcome; D014330:Tropical Medicine
chemical_list: D000900:Anti-Bacterial Agents; D000962:Antimalarials; D002981:Clindamycin; D011803:Quinine